170 related articles for article (PubMed ID: 16981986)
1. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
von Mach MA; Burhenne J; Weilemann LS
BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
[TBL] [Abstract][Full Text] [Related]
2. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis.
Burkhardt O; Thon S; Burhenne J; Welte T; Kielstein JT
Int J Antimicrob Agents; 2010 Jul; 36(1):93-4. PubMed ID: 20381320
[No Abstract] [Full Text] [Related]
3. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.
Alvarez-Lerma F; Allepuz-Palau A; Garcia MP; Angeles Leon M; Navarro A; Sanchez-Ruiz H; Iruretagoyena JR; Luque-Gomez P;
J Chemother; 2008 Feb; 20(1):93-100. PubMed ID: 18343750
[TBL] [Abstract][Full Text] [Related]
4. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
[TBL] [Abstract][Full Text] [Related]
6. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
8. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
11. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole-induced photosensitivity.
Malani AN; Aronoff DM
Clin Med Res; 2008 Sep; 6(2):83-5. PubMed ID: 18801950
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.
Luke DR; Wood ND; Tomaszewski KE; Damle B
Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395
[TBL] [Abstract][Full Text] [Related]
16. [Voriconazole compromises renal function in an elderly CDK patient with Candida albicans infection].
Anastasio P; Marcarelli F; Bilancio G; Mele AA; De Santo NG
G Ital Nefrol; 2010; 27(3):306-11. PubMed ID: 20540025
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
18. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
19. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Trifilio S; Pennick G; Pi J; Zook J; Golf M; Kaniecki K; Singhal S; Williams S; Winter J; Tallman M; Gordon L; Frankfurt O; Evens A; Mehta J
Cancer; 2007 Apr; 109(8):1532-5. PubMed ID: 17351937
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
